| Aug 7 |
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
|
| Jul 29 |
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
|
| Jul 25 |
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
|
| Jul 18 |
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
|
| May 21 |
Peering Into ZyVersa Therapeutics's Recent Short Interest
|
